| Literature DB >> 32486911 |
Smriti Sharma1,2, Sumit Sharma2,3, Parvinder Pal Singh2,3, Inshad Ali Khan1,2.
Abstract
A new member of the class metallo-β-lactamase (MBL), New Delhi metallo-beta-lactamase 1 (NDM-1) has emerged recently as a leading threat to the treatment of infections that have spread in all major Gram-negative pathogens. The enzyme inactivates antibiotics of the carbapenem family, which are a mainstay for the treatment of antibiotic-resistant bacterial infections. This review provides information about NDM-1 spatial structure, potential features of the active site, and its mechanism of action. It also enlists the inhibitors/compounds/drugs against NDM-1 in various development phases. Understanding their mode of inhibition and the structure-activity relationship would be beneficial for development, synthesis, and even increasing biological efficacy of inhibitors, making them more promising drug candidates.Entities:
Keywords: MBL; NDM-1 inhibitors; beta lactamase; developmental phase; multi drug resistant; peptidoglycan
Year: 2020 PMID: 32486911 DOI: 10.1089/mdr.2019.0315
Source DB: PubMed Journal: Microb Drug Resist ISSN: 1076-6294 Impact factor: 3.431